• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
      • Overview
      • Join NACs Network
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

General consultation on clinical breakpoints for Vibrio species

General consultation on clinical breakpoints for Vibrio species 1 October - 15 November. Use the form available on the consultation webpage to comment. Queries can be addressed to gunnar.kahlmeter@eucast.org.

Get to know more

Streptococcus pneumoniae and benzylpenicillin susceptibility testing.

We are frequently asked questions regarding (1) EUCAST Warning No. 7 : is this warning specifically directed at benzylpenicillin gradient tests (Etest TM , bioMérieux, and MTS TM , Liofilchem) when used for Streptococcus pneumoniae or does it apply to other bacteria, (2) is it still valid or have we…

Get to know more

Company Rationale Document template revised

Companies are requested to complete a "company rationale document" to aid the EUCAST process of setting breakpoints for new agents. A template has been available for many years. It is now revised .

Get to know more

Publication in JAC of Vibrio spp methods and material for breakpoints

Publication in Journal of Antimicrobial Chemotherapy: Vibrio species - development of EUCAST susceptibility testing methods and MIC and zone diameter distributions on which to determine clinical breakpoints . Onur Karatuna et al. December 2023.

Get to know more

Advising industry on developing EUCAST MIC and Zone diameter data

The web page " Information for industry " has been supplemented with more information; specifically on the development of disks (content) and of reference MIC and Zone diameter material for EUCAST decisions on breakpoints.

Get to know more

A new version of the breakpoint table (13.1) published. Additional agents for anaerobes.

The breakpoint tables have been updated from 13.0 (1 Jan, 2023) to 13.1 (29 June, 2023). This allows the AST of several additional agents for anaerobic bacteria. There is a matching update of QC tables.

Get to know more

Updated warning on cefiderocol AST

Investigations into the problems with susceptibility testing of species with breakpoints for cefiderocol have been performed by EUCAST and others. The warning has been updated 16 August, 2022. Work is continued and further updates may be expected.

Get to know more

The 2023 preliminary breakpoint table now available for comments and questions.

The next breakpoint table (valid from 1 Jan, 2023) is now available for comments and questions. Please address comments to erika.matuschek[at]eucast.org or gunnar.kahlmeter[at]eucast.org no later than 19 December, 2022.

Get to know more

Organisation

Organisation The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is mandated by ESCMID, EMA, ECDC, EFSA and partners across Europe to define, harmonize and standardize antimicrobial breakpoints and testing methods. EUCAST structure and procedures have been developed with ESCMID,…

Get to know more

Planned updates to breakpoint table v 11.0

Striving to keep EUCAST users informed of upcoming changes, this short document describes the planned major changes to the breakpoint tables v 11.0 (2021). The table itself will be published for consultation on or about 5 December, 2020.

Get to know more
Show more results
© EUCAST 2026. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies